EU employment and health ministers on 16 June 2026 adopted the general approach on the European Biotech Act directive, but the debate exposed persistent divisions over weakened monitoring of genetically modified microorganisms (GMMs), clinical trial procedures, and supplementary protection certificate (SPC) extension. The Cyprus Presidency framed the directive as a competitiveness and safety priority, while Commissioner Olivér Várhelyi urged rapid progress on biotech, faster clinical trials, and biosimilar entry. Commissioner Hadja Lahbib outlined the EU's coordinated Ebola response, which drew broad support.
On GMM classification, Austria and Slovakia opposed the directive, arguing it would weaken monitoring and reduce Commission oversight. Poland and Hungary abstained or flagged concerns, reflecting a north-south and east-west split on risk governance. On clinical trials, Spain and Slovenia pushed for ethics committee centrality, while Denmark and Belgium demanded faster cross-border procedures, pulling in opposite directions on procedural speed versus ethical safeguards. On SPC extension, Italy, Poland, Malta, and the Netherlands questioned affordability and biosimilar access, while Austria and Czechia supported the measure, exposing a cleavage between member states prioritising innovation incentives and those concerned about public health costs.
On medical devices, Italy rejected an EMA role in classification, and Poland stressed cybersecurity requirements. On AOB, more than 16 member states warned that the wastewater directive's extended producer responsibility could harm medicine supply; Greece requested a delay. Despite these divergences, consensus existed on strengthening biotech competitiveness, simplifying medical device rules, and coordinating the Ebola response. Ireland pledged follow-up on devices and remaining Biotech Act chapters.
Biotech firms stand to benefit from faster clinical trials and SPC extension, but biosimilar producers and generics companies may face delayed market entry if SPC extension is adopted. National health systems could see higher medicine costs under SPC extension, while patients may gain from accelerated access to innovative therapies. The GMM classification dispute affects environmental safety groups and biotech researchers, with weaker monitoring potentially lowering compliance costs for industry but raising risks for ecosystems. The wastewater directive's producer responsibility extension would shift costs to pharmaceutical manufacturers, potentially affecting medicine supply and prices for consumers.